Skip to main content

Table 4 Data for subjects that completed all visits (n = 12)

From: Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial

   SC BL PUR118 PUR118 PUR118
2.8 mg dose 5.5 mg dose 11.0 mg dose
Sputum:       
Viability % 84.5 (12.4) 85.5 (12.1) 81.1 (13.0) 82.2 (13.3) 85.0 (11.6)
TCC 106/mL 1.6 (0.9) 2.7 (1.9) 3.6 (3.2) 2.2 (1.4) 3.4 (4.7)
AM % 62.0 (23.9) 27.2 (16.4) 23.7 (22.4) 16.6 (18.6) 16.2 (21.2)
CD14 + MO % 2.3 (1.8) 5.9 (2.2) 7.9 (4.5) 5.3 (3.6) 6.1 (3.6)
NG % 29.5 (23.0) 63.7 (23.4) 58.1 (21.4) 71.0 (23.4) 69.3 (22.0)
LY % 1.5 (1.6) 1.1 (1.4) 0.6 (0.4) 0.7 (0.6) 0.8 (0.6)
EO % 0.0 (0.5) 0.3 (0.5) 0.5 (0.6) 0.5 (0.7) 0.3 (0.3)
FE % 2.8 (5.8) 1.3 (3.0) 9.8 (11.8) 2.7 (7.7) 3.4 (5.5)
AM 106/mL 0.9 (0.5) 0.6 (0.7) 0.7 (0.6) 0.4 (0.4) 0.5 (0.6)
CD14 + MO 106/mL 0.0 (0.1) 0.2 (0.1) 0.2 (0.2) 0.2 (0.1) 0.2 (0.2)
NG 106/mL 0.2 (0.6) 1.7 (1.9) 2.1 (2.5) 1.5 (1.3) 2.3 (3.2)
EO 106/mL 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
LY 106/mL 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
FE 106/mL 0.1 (0.1) 0.0 (0.1) 0.2 (0.2) 0.1 (0.2) 0.1 (0.2)
Blood:       
WBC 106/mL 4.5 (1.4) 8.6 (1.9) 8.2 (2.6) 8.3 (2.3) 8.4 (2.8)
NG % 56.5 (9.5) 67.8 (9.2) 63.3 (11.2) 64.1 (4.0) 64.3 (6.1)
MO % 10.3 (2.3) 7.8 (2.1) 8.3 (1.8) 8.3 (2.0) 7.8 (2.4)
LY % 28.1 (11.8) 22.0 (8.6) 24.5 (10.8) 24.4 (7.4) 23.9 (5.1)
EO % 2.1 (1.8) 1.5 (1.2) 2.2 (1.3) 1.8 (0.9) 1.7 (0.4)
BA % 0.7 (0.3) 0.3 (0.1) 0.3 (0.1) 0.4 (0.3) 0.4 (0.2)
  1. Median and interquartile ranges. Sputum was obtained and analysed at the screening visit (SC) and following four ozone challenges with no treatment (BL) or treatment with 2.8 mg, 5.5 mg or 11 mg doses of PUR118. Repeated measures ANOVA including BL, 2.8 mg, 5.5 mg or 11 mg doses showed no significant changes
  2. TCC total cell count, AM macrophages, NG neutrophils, LY lymphocytes, EO eosinophils, FE bronchial epithelial cells, MO monocytes, WBC leucocytes, BA basophils
\